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Background: Oral care is important for oral and systemic health, especially for elderly institutionalized individuals
and compromised patients. However, conventional mechanical plaque control is often difficult for these patients
because of the pain or the risk of aspiration. Although antimicrobial photodynamic therapy (aPDT), which is
considered an alternative or adjunct to mechanical approaches, has potential application as a less stressful method
of daily plaque control, no clinical application of this technique has been reported.
Methods: We investigated the inhibitory effect of a combination of toluidine blue O (TBO), and a red light-emitting
diode (LED) on dental plaque formation in healthy volunteers. The optimal concentration of TBO was determined
in preliminary in vitro experiments to evaluate the bactericidal effect of aPDT on Streptococcus oralis and to clarify
its safety in fibroblast cells. To survey the mechanism of TBO-mediated aPDT, the quality and quantity of reactive
oxygen species (ROS) generated during aPDT were also examined using electron spin resonance (ESR) spectroscopy.
Subsequently, the inhibitory effect of aPDT on dental plaque formation was investigated in eleven subjects as a clinical
pilot study. The right or left mandibular premolars were randomly assigned to the treatment (with aPDT) or control
(without aPDT) groups. In total, aPDT was applied six times (twice per day) to the teeth in the test group over a period
of four days. On the fourth day, the study concluded and the analyses were performed.
Results: A combination of 500 or 1000 μg/ml TBO and LED irradiation for 20 s significantly decreased the number of
colony forming units of Streptococcus oralis. The cytotoxicity of aPDT was comparable to that of standard antiseptics
used in the oral cavity. Hydroxyl radicals were detected by ESR analysis, but singlet oxygen was not. A randomized
controlled trial demonstrated that aPDT with 1000 μg/ml TBO and red LED irradiation significantly suppressed dental
plaque formation without harming teeth or the surrounding tissues.
Conclusions: aPDT has the potential to be a promising novel technical modality for dental plaque control.
Trial registration: This trial was registered with University Hospital Medical Information Network Clinical Trials Registry
(number UMIN000012504).
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Antimicrobial photodynamic therapy (aPDT) is a proced-
ure in which oxygen-dependent activation of a photosen-
sitizer by light (mainly lasers) leads to the generation of
cytotoxic reactive oxygen species (ROS). Recently, this
procedure was introduced in the medical [1,2] and dental
[3-6] fields. Besides confirmation of its antimicrobial po-
tential in vitro [7,8], prior clinical studies have evaluated
the application of aPDT for the treatment of acne vulgaris
in dermatology [9], and of periodontal [10,11], endodontic
[12,13], and peri-implant [14] disease in dentistry. Further,
since it uses light-generated compounds, aPDT may be
able to eradicate multidrug-resistant bacteria without
influencing the emergence of further resistance in those
bacteria [15].
Increasing evidence exists that oral care is critical for
systemic health, especially in compromised patients. Previ-
ously, Yoneyama et al. reported that good oral care lowers
the risk of pneumonia and the rate of mortality in elderly
institutionalized individuals [16,17]. Abe et al. also sug-
gested that oral hygiene was effective in the prevention of
influenza [18]. The US National Institutes of Health (NIH)
has recommended that “all cancer patients should have an
oral examination before the initiation of cancer therapy,
and the treatment of preexisting or concomitant oral
disease is essential in minimizing oral complications in all
cancer patients” [19]. Conventionally, mechanical tools
such as a toothbrush, dental floss, or sponge brush accom-
plish the removal of dental bacterial plaque. However,
mechanical plaque control is technically demanding, and
can be physically stressful for subjects with a decreased
range of arm motion, or a medical condition that impedes
them from maintaining good oral hygiene. Therefore, the
application of a non-mechanical means for controlling
dental plaque formation could be of wide interest.
In 1993, Wilson et al. [20] proposed aPDT as an alter-
native to pharmaceutical and mechanical means of elim-
inating dental bacterial plaque. However, there are no
clinical reports on the use of aPDT as a preventive oral
care method for the control of dental plaque formation.
If aPDT could be used as a novel method to control
dental plaque formation, patients may be able to re-
ceive efficient oral care without the unpleasant stresses
that accompany conventional mechanical tooth cleaning,
such as bleeding or pain.
Accordingly, we aimed to investigate the inhibitory ef-
fects of aPDT in the oral cavity of healthy volunteers as
a pilot study, prior to the clinical trial involving actual
patients. We focused on toluidine blue O (TBO), which is
a classic photosensitizer of phenothiazinium salt, because
its bactericidal effects were already clarified in previous
in vitro studies [8,21-23], as well as in the treatment of
periodontitis [4]. Further, the bactericidal effects of TBO-
mediated aPDT using high-power red light-emitting diode(LED) on two typical periodontopathic bacteria, Porphyro-
monas gingivalis and Aggregatibacter actinomycetemcomi-
tans, have also been demonstrated in vitro [3].
Before the pilot study in healthy volunteers, the anti-
microbial effects of aPDT on Streptococcus oralis (S. oralis),
one of the typical facultative anaerobic bacterium in human
dental plaque, and the cytotoxic effect of aPDT on fibro-
blasts, were examined in vitro. Further, the characterization
of ROS generated during aPDT treatment was investigated
by electron spin resonance (ESR).
Methods
Experiment 1: In vitro evaluation of bactericidal effects of
aPDT on Streptococcus oralis
Preparation of bacterial planktonic suspension
S. oralis OMZ 607 was maintained on blood agar plates
(E-MP23; Eiken Chemical Co. Ltd., Tochigi, Japan) at
37°C under aerobic conditions. A loopful of each strain
was inoculated in 9 ml brain heart infusion (BHI) broth,
and cultured anaerobically at 37°C for 16 h. Afterwards,
500 μl of the bacterial cell suspension was transferred
into 5 ml of fresh BHI broth, and further incubated
anaerobically at 37°C for approximately 5 h. Finally, a
bacterial suspension of 108 cells/ml was prepared using
a counting chamber, and stored on ice until use.
Photosensitizer and light source
Toluidine blue O (TBO) powder (maximum absorption =
626 nm, Sigma, St. Louis, MO) was dissolved at con-
centrations of 100, 500, and 1000 μg/ml in sterile saline
solution. A prototype high-power red LED device (ac-
tive elements = AlInGaP, wavelength = 600–700 nm, peak
wavelength = 660 nm, power density = 1.1 W/cm2, spot
size = 9 mm at the device end; modified from Pencure™
with a 660 nm band Deep Red LED [LZ1-00R205;
LedEngin, Inc., Santa Clara, CA] by J Morita Mfg. Kyoto,
Japan) was used as the light source. The irradiation time
of LED was fixed at 20 s, according to the results of our
previous in vitro study [3], which demonstrated effective
bacterial elimination using the TBO-mediated aPDT pro-
cedure with 20 s irradiation.
Lethal photosensitization
A 30-μl aliquot of bacterial suspension was mixed with
saline solution or an equal volume of TBO solution at
the various concentrations (100, 500, and 1000 μg/ml) in
the wells of a sterile 96-well flat bottom plate (Falcon®;
Becton Dickinson Co., NJ). The final concentrations of
TBO in the mixed solution were 50, 250, and 500 μg/ml,
respectively. After incubation at room temperature for
20 s, LED irradiation was performed for 20 s. The light-
emitting end (diameter = 8 mm) of the LED was positioned
to correspond with the opening of the well (diameter =
7 mm) during irradiation. The distance between the top
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emitting end was 7 mm, and the depth of the mixed
solution was 3 mm. The actual power at the bacterial
suspension surface was 310 mW, and the power density
was calculated to be 0.94 W/cm2 (total energy 6.2 J
for 20-s irradiation). Each bacterial suspension was indi-
vidually exposed to LED irradiation after preparation of
the suspension in each well. A total of 7 experimental
groups (exposure to 100, 500, 1000 μg/ml TBO only, com-
bination of TBO and 20 s LED irradiation, and 20 s LED
irradiation only) and one untreated control group were
prepared for each one well.
After treatment, a 10-μl aliquot from each well was
serially diluted 102–105-fold with saline solution, and
10 μl of the diluted samples were plated in triplicate on
blood agar plates. All of the procedures including solu-
tion preparation, irradiation, and plating samples were
performed for each well individually (i.e. one by one). The
96-well plates were incubated aerobically at 37°C for 48 h,
and the numbers of colony-forming units (CFUs) were
determined. The experiment was repeated independently
five times.
Experiment 2: cytotoxic effect of aPDT on fibroblasts
Cell culture
Mouse fibroblast cell line L929 (Riken, Saitama, Japan)
was cultured in 75 cm3 tissue culture flasks in 20 ml RPMI
1640 medium (Nacalai Tesque, Kyoto, Japan) containing
100 U/ml penicillin, 100 U/ml streptomycin, and supple-
mented with 2.5 mmol/l L-glutamine and heat-inactivated
5% fetal calf serum (Gibco®).
Cell treatment
1 × 104 cells were seeded into each well of 96-well black
assay plates (clear flat bottom; Costar®; Corning, NY),
and incubated at 37°C in a humidified incubator with 5%
CO2 for 48 h until the cell monolayer became confluent.
For experimental groups, after removal of the medium,
100-μl TBO (100, 500, or 1000 μg/ml) was added to
each well. Cells were incubated for 20 s, and the TBO
solution was then aspirated from all wells. After the cells
were washed twice with 100-μl PBS, 100-μl medium was
added to the well, and immediately the cell was exposed
to LED light from the top of the plate at 0.94 W/cm2 for
20 s (total energy = 6.2 J). The controls were either un-
treated, or treated with TBO (100, 500, and 1000 μg/ml)
only, and were washed twice with PBS.
The group of cells treated with 1000 μg/ml TBO and
LED was compared with a group of cells treated with 2.5–
3% H2O2 (Oxydol; Yoshida Pharmaceutical Co. Ltd.,
Saitama, Japan), or 0.025% benzalkonium chloride (OSVAN®;
Nihon Pharmaceutical Co. Ltd., Tokyo, Japan), which are
the standard antiseptics for oral mucosa. The cells were
exposed to H2O2 and benzalkonium chloride for 20 s, andwashed twice with PBS. All experiments were performed
in triplicate and repeated five times.
Cytotoxicity assay
A colorimetric assay containing the tetrazolium compound
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS (CellTiter
96® Aqueous One Solution Cell Proliferation Assay;
Promega, WI), was used to determine cell viability [21].
About 100-μl aliquots of growth medium and 20 μl of
MTS reagent were added to each well. Following incuba-
tion for 2 h at 37°C in a 5% CO2 incubator, the absorbance
of each well was measured at 490 nm using a microplate
reader, and cell viability was calculated.
Experiment 3: analysis of ROSs generated during aPDT
ESR spectroscopy was used for the qualitative and quan-
titative evaluation of ROS generated during aPDT. The
spin trap reagents 2,2,6,6-tetramethyl-4-piperidinol (4-OH-
TEMP; 98% purity; Sigma), and 5,5-dimethyl-1-pyrroline-
N-oxide (DMPO; Dojin Chemicals, Kumamoto, Japan)
were used for singlet oxygen and hydroxyl radical de-
tection, respectively. A mixture of 800-μl PBS, 100-μl
1000 μg/ml TBO, and 100-μl 4-OH-TEMP was used for
measuring singlet oxygen. A mixture of 400-μl PBS, 50-μl
50 mM DMPO, and 50-μl of 1000 μg/ml TBO was used
to measure hydroxyl radicals. Measurements were ob-
tained after transfer of the mixtures to a quartz flat cuvette
and exposure to the red LED light for 20 s. The measure-
ment was performed using ESR (JES-RE 3X, JEOL; Tokyo,
Japan) connected to a WIN-RAD ESR Data Analyzer
(Radical Research, Tokyo, Japan) at the following instru-
ment settings: microwave power = 8 mW, magnetic field =
335.8 mT, modulation width = 0.079 mT, sweep time =
1 min, and time constant = 0.03 s. All experiments were
performed in triplicate at room temperature.
Experiment 4: inhibition effect of aPDT on dental plaque
formation
An open randomized single-blinded clinical trial with
split-mouth design (each subject received test and control
treatments, each to a separate side of the mouth) was con-
ducted to investigate the inhibitory effect of aPDT on den-
tal plaque formation (Figure 1).
Subjects
This clinical trial was approved by the Ethics Committee
of the Faculty of Dentistry, Tokyo Medical and Dental
University (TMDU) (No. 836), and was performed in ac-
cordance with the Declaration of Helsinki. This trial was
registered with University Hospital Medical Information
Network Clinical Trials Registry (number UMIN000012504)
and was performed by following the CONSORT guide-
lines for clinical trials Additional file 1. The recruitment
Figure 1 Consort flow diagram of the clinical trial of the effectiveness of aPDT for inhibition of dental plaque.
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2013 to February 2013 at Department of Periodontics,
Dental Hospital of TMDU.
Eleven volunteer dentists were recruited for this
study, and informed consent was obtained from all
participants. The subjects included seven men and four
women, aged 26–33 years (mean = 28.0 ± 2.3 years).
Inclusion criteria for subject enrollment included good
general health, no antimicrobial intake in the last three
months, the presence of at least 20 teeth, the normal
eruption of all mandibular premolars, the absence of
swelling or redness of the gingiva, and the absence of
sites with probing depth ≥ 4 mm.Sample size calculation
The sample size was calculated using a statistical power
of 80%, Type I error rate of 5%, and an assumed differ-
ence of 10% and SD of 10% with the values of plaque
deposition area. On the basis of these data, the num-
ber of subject required to conduct this study was
calculated as 10. However, considering the possibility
of having one drop-out subject, enrollment of 11
participants was planned.The aPDT procedure
The first and second premolars on the left and right
sides of the mandible were evaluated. The selection of
teeth was based on location, and suitability for LED
irradiation, photographing, and sample collection, as
well as plaque accumulation given the study conditions.
The clinical trial was performed over four days, begin-
ning and ending in the evening (Figure 1). On the first
day, the dental plaque deposited on the buccal and
lingual surfaces of the mandibular premolars on both
sides was dyed red with a plaque disclosing solution
(PROSPEC®; GC, Tokyo, Japan). The supra- and sub-
gingival plaque was then thoroughly removed by profes-
sional tooth cleaning (PTC) using an ultrasonic scaler, as
well as a rubber cup and a cone-shape brush mounted
on a micromotor handpiece.
Subsequently, the right or left side premolars were
randomly assigned for treatment (with aPDT) or as non-
treated controls (without aPDT) by using the envelope
method, in which the participants randomly selected an
opaque envelope containing a note allocating the treat-
ment side (right or left).
TBO (1 mg/ml) was gently applied to the buccal and
lingual surfaces of the test group teeth using a small
Ichinose-Tsuno et al. BMC Oral Health 2014, 14:152 Page 5 of 10
http://www.biomedcentral.com/1472-6831/14/152cotton pellet. After 10 s, TBO was washed away by
rinsing the mouth. After washing, LED was focused
at a 90° angle on each buccal and lingual surface of
each tooth for 20 s, resulting in a total irradiation
time of 80 s on the four surfaces of two premolars in
each treatment session (Figure 2). In total, aPDT was
applied six times (twice per day, once in the morning,
and once in the evening) to the test group teeth for
four days. During the trial period, the participants
were prohibited from brushing the premolar and the
adjacent teeth, and from using mouthwash. On the
fourth day, the study concluded and analyses were
performed.
Determination of the area of dental plaque deposition
After the tooth surfaces were dyed with a plaque-
disclosing solution, the buccal and lingual aspects of
the first and second premolars in the treatment and con-
trol groups were photographed at a 90° angle to the tooth
surface. The lingual photographs were taken with a mirror
designed especially for mandibular lingual photo-
graphy (Photographic Mirror ST for Lingual 13262,
YDM Corp., Tokyo, Japan). The red color-stained area
of dental plaque deposition, as well as the area of the
whole tooth surface on the buccal and lingual sides,
was determined on the photographs using a software
program (Photoshop CS5 Extended; Adobe Systems
Inc., CA). To reduce interobserver variability, the
determination of the areas was performed independ-
ently for each site by two examiners blinded to the
experimental groups (A. A. and Y. T.), and the aver-
age of the two measurements was used as the repre-
sentative area value of each site. The percentage of
the area of plaque deposition relative to the total
tooth surface was calculated.Figure 2 Photographs showing the aPDT clinical procedure. (A) Before
procedure). (C) During the application of TBO. (D) After the application of TBODetermination of the number of bacteria in dental plaque
collected from the lingual surface of second premolars
The lingual surface of the second premolars was selected as
the representative site for plaque collection, because the lin-
gual surface usually has more constant plaque accumulation
than the buccal surface, and the second premolar has a lar-
ger lingual surface than the first premolar. Supragingival
plaque samples were collected with a Gracey curette from
the lingual surface of the second premolar prior to treat-
ment (baseline), and 4 days after completion of the clinical
trial by blinded examiners (A. A. or Y. T). The number of
bacteria was measured using a bacterial counter available at
the chair side (Rapid oral bacteria detection apparatus;
Panasonic Healthcare, Tokyo, Japan) that was suitable for
rapidly counting a large number of bacteria. The counter
device employed the dielectrophoretic impedance measure-
ment method, which has been reported to demonstrate a
good correlation with the conventional culture method [24].
Statistical analysis
Data from the first experiment were evaluated using
analysis of variance (ANOVA), followed by Dunnett’s test.
The influence of TBO and LED irradiation on fibroblasts
was analyzed using two-way factorial ANOVA, followed
by Tukey’s test. The comparison of the combined applica-
tion of 1000 μg/ml TBO and LED irradiation with the two
known antiseptics was performed with ANOVA, while the
amount of ROS generated during aPDT was analyzed
using a t-test. Data from the fourth experiment were
analyzed using a paired t-test. All analyses were performed
using the statistical software program JMP 8.0 (SAS
Institute, Cary, NC), with the exception of the two-way
factorial ANOVA, which was performed by PASW 18.0
(SPSS, IBM, Tokyo, Japan). A P < 0.05 was considered
statistically significant for all analyses.aPDT. (B) After initial removal of the dental plaque (before the first aPDT
and mouth-rinsing. (E) During LED irradiation. (F) After LED irradiation.
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Experiment 1: bactericidal effect of aPDT on S. oralis in vitro
In the groups treated with either LED or TBO alone, the
numbers of CFUs did not differ from those of the untreated
control. Conversely, groups that received TBO+ LED ex-
hibited numbers of CFUs that were significantly lower at
500 and 1000 μg/ml (P < 0.01 and P < 0.05, respectively),
compared to the control. The lowest number of CFUs was
observed in the group treated with 500 μg/ml TBO+ LED
(1.42 log reduction, 96.2% killing rate, Figure 3).
Experiment 2: cytotoxic effect of aPDT on fibroblasts
TBO alone caused a dose-dependent decrease in cell via-
bility. Two-way factorial ANOVA revealed that LED, TBO,
and TBO+LED significantly reduced cell viability (P < 0.01).
Additionally, the application of LED to all concentra-
tions of TBO enhanced the reduction in cell viability
(Figure 4A). However, the viability of cells treated with
1000 μg/ml TBO and LED irradiation was not significantly
different from the viability of cells treated with 2.5–3%
H2O2 or 0.025% benzalkonium chloride (Figure 4B).
Experiment 3: analysis of ROSs generated during aPDT
No significant differences existed in the production of
singlet oxygen between the PBS + LED and the TBO +
LED groups (Figure 5A). However, when compared to the
control, the production of hydroxyl radical was signifi-
cantly higher in the TBO+ LED group (P < 0.01, Figure 5B).
The specific DMPO-OH spin adduct, which proves the
production of hydroxyl radical, was observed in the TBO+
LED group (Figure 6).
Experiment 4: inhibition effect of aPDT on dental plaque
formation
No systemic or local complications were observed after
aPDT application during the experimental period. TheFigure 3 In vitro bacterial reduction effects of aPDT with TBO
and LED on S. oralis. Blue bars show the effect of TBO only, and
red bars present the effect of TBO with LED irradiation. The data
represent mean ± SD (n = 5).residual blue staining on the gingiva following TBO ap-
plication was not visible macroscopically, and was only
noted immediately after application. The staining was both
minimal and temporary, and caused no esthetic problems
for the subjects.
The plaque formation on the aPDT group teeth was ob-
viously inhibited after day four of aPDT, which was appar-
ent in representative intraoral photographs (Figure 7). The
percentages of plaque deposition areas to total buccal
(Figure 8A) and lingual tooth surfaces (Figure 8B) were
significantly reduced in the aPDT group (buccal = 14 ±
9.1% and lingual = 12 ± 5.4%, mean ± SD, respectively),
compared to the control group (buccal = 25 ± 13% and lin-
gual = 21 ± 7.0%, respectively; P < 0.01).
No significant differences were detected at baseline be-
tween the aPDT group (6.17 ± 0.38 log) and the control
group (6.29 ± 0.39 log; P = 0.49) in the total number of
bacteria in the dental plaque collected from the lingual
surface of the second premolar. However, the total num-
ber of bacteria in the dental plaque was significantly
lower 4 days after the clinical trial in the aPDT group
(6.17 ± 0.49 log) compared to the control group (6.68 ±
0.48 log; P < 0.01; Figure 9).
Discussion
To our knowledge, this is the first clinical trial to dem-
onstrate the effectiveness of aPDT in inhibiting dental
plaque formation on teeth without inducing harmful ef-
fects to host tissues. Further, this study confirmed that
TBO with red LED effectively reduced the bacteria S.
oralis, which is known as an initial colonizer in dental
plaque formation, and is often detected in the blood of
patients who suffer from infectious endocarditis [25,26].
The use of TBO with a high-power LED device and a 20 s
irradiation time, led to a significant dose-dependent re-
duction in CFUs in vitro. However, the reduction was less
when 1000 μg/ml TBO (final concentration of 500 μg/ml)
was used than when 500 μg/ml (final concentration of
250 μg/ml) was applied. A possible explanation was the
fact that the blue-colored 1000 μg/ml TBO mixed bacter-
ial solution was too dark for the red light to penetrate
through the solution to the bottom of the 96-well plate,
and thus the sensitization of TBO by LED irradiation was
potentially blocked. Nonetheless, 1000 μg/ml TBO was
used because in clinical situations, the immediate dilution
of TBO with saliva and its superficial spread on the tooth
surface could lead to the more efficient light sensitization
of TBO than witnessed in vitro. In the present study, the
focus was only on S. oralis; however, the formation of den-
tal biofilm consists of different primary colonizers and
complex inter-microbial interactions. Therefore, several
other plaque forming bacteria including Actinomyces
viscosus and Streptococcus sanguis should be investigated
in future studies.
Figure 4 Cytotoxic effects of aPDT on fibroblasts. (A) The effect of TBO concentration on cell viability. (B) Comparison of cell viability between
aPDT and standard antiseptics. The data represent mean ± SD (n = 5).
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negatively influenced the viability of fibroblasts in a
concentration-dependent manner, and the application
of LED enhanced the affect. However, the in vitro reduc-
tion in cell viability under the present aPDT conditions
(1000 μg/ml TBO with 20 s LED irradiation) did not ex-
ceed that observed with other antiseptics, which indicated
that the cytotoxicity of aPDT was within the conventional
levels. Additionally, although prior reports have indicated
the resistance of bacteria to antiseptics such as benzalko-
nium chloride, which is a quaternary ammonium cationic
surfactant that interrupts the lipid membrane of cells
[27,28], the lack of bacterial resistance following applica-
tion of aPDT would be another benefit in clinical applica-
tion [29]. In the present study, however, we only observed
acute cytotoxicity at 2 h after single application of aPDT,
and thus further studies are required to investigate the
long-term influence of aPDT on cell proliferation, as well
as the cumulative action following repeated applications.Figure 5 ROSs detected during the TBO-mediated aPDT procedure.
(A) Singlet oxygen. (B) Hydroxyl radical.The analysis of ROS generated during TBO-mediated
aPDT resulted in the novel finding that the hydroxyl
radical was the primary product. Although the mechan-
ism of aPDT [30] is generally thought to take place by a
Type I process, which produces a hydroxyl radical by
electron transfer, or a Type II process, which yields sing-
let oxygen by energy transfer, no modality of cell death
by TBO-mediated aPDT has been clarified. Singlet oxy-
gen is regarded as the major damaging species in aPDT
[31], and the common photosensitizer methylene blue is
a known producer of singlet oxygen. In our previous pilot
study (data not shown), we confirmed the production of
singlet oxygen in methylene blue-mediated aPDT. How-
ever, ESR analysis clearly revealed that the hydroxyl radical
was the predominant product of TBO-mediated aPDT.
Further, Type I machinery was speculated to play an
important role in this aPDT procedure.Figure 6 Typical ESR spectrum during TBO-mediated
aPDT procedure.
Figure 7 Results of a clinical trial of the effectiveness of aPDT for inhibition of dental plaque. Photographs of mandibular premolars of
subject #6 after aPDT. Buccal (A) or lingual (C) surface of aPDT group teeth, and buccal (B) or lingual (D) surface of control teeth.
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we attempted the clinical application of aPDT for the
inhibition of dental plaque formation, and observed a
significant suppression of plaque deposition on teeth
treated with aPDT. The four day duration of the clin-
ical trial was short, and thus a longer duration wasFigure 8 The ratio of the plaque-deposited area to the total area of bdesirable. However, the duration of this pilot study was
limited to four days, due to consideration of the phys-
ical and mental stresses caused by prohibiting tooth
brushing, and the concerns of volunteer dentists
regarding the occurrence of tooth decay and gingival
inflammation.uccal (A) and lingual (B) tooth surface in mandibular premolars.
Figure 9 The number of bacteria in dental plaque collected
from the second premolar.
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approach by Dosselli et al. [32] revealed that aPDT
delays the growth of bacteria, and reduces the capacity of
bacteria for glucose consumption. Combined, the bacterial
killing effect and the retardation of bacterial growth with
aPDT could reduce plaque deposition on teeth.
Nonetheless, the negative aspects of the clinical use of
aPDT should be considered. Some reports have noted
tooth staining with TBO [33], however, residual staining
of teeth and gingival tissue with TBO after the aPDT
procedure was not visible, and did not present a prob-
lem in this clinical trial. Additionally, light energy has a
biological effect on the activations of cells and tissues.
Therefore, various positive and negative effects of the
irradiation of teeth and gingival tissues, such as reducing
gingival inflammation or inducing the calcification of
dental pulp [34], need to be clarified. In particular, al-
though the performance of aPDT was only short term in
this present study, more attention to the cumulative
action of potential side effects should be paid in the
long-term repeated usage for daily plaque control.
Additionally, in this clinical trial, the reduction rate in
the plaque-deposition area was on average no more than
approximately 56% following aPDT treatments, probably
because the susceptibility of bacteria to aPDT was thought
to be much lower in biofilms than in the planktonic con-
dition [35]. Hence, modification of the system for delivery
of the photosensitizer into the biofilm should be examined
for the effective enhancement of the inhibitory effects ofaPDT on dental plaque formation. An example of a
possible modification is the use of an antibody conjugated
to photosensitizers [36]. Similarly, the optimal power and
time of LED irradiation, in combination with the frequency
of aPDT procedure, should be clarified. In addition, the
present pilot study was limited by the employment of
healthy volunteer dentists as subjects, as well as by the
small number of participants and the short duration of the
clinical trial. Consequently, further investigations involving
suitable conditions for clinical plaque control in a larger
number of subjects and for a longer trial duration are
required to confirm the safe and effective aPDT proced-
ure compared with conventional treatments. In the
future, aPDT could be used for plaque control at an office
equipped with a specific appliance, or at home with the
combination of tooth paste containing a photosensitizer
and a light-emitting toothbrush [5].
Conclusions
The application of aPDT significantly suppressed the
formation of dental plaque, which indicated that aPDT
may be a promising alternative or adjunct method to
mechanical means in dental plaque control for oral care.
This study provides initial data on a potentially new ap-
proach, and thus further validation to determine optimum
conditions including dye concentration, the modification
of dye application, the light power, and the frequency
of the procedure, as well as any potential adverse effects,
are required in order to establish a safe and effective aPDT
procedure.
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